A Polymorphic −844T/C in <i>FasL</i> Promoter Predicts Survival and Relapse in Non–Small Cell Lung Cancer

Abstract

FasL -844T/C polymorphism may predict survival and relapse in NSCLC. We suggest that FasL may be a molecular target for immunotherapeutic interventions to improve the clinical outcome of patients with NSCLC. This finding should be validated by another investigative group.